

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
25 April 2002 (25.04.2002)

PCT

(10) International Publication Number  
**WO 02/32879 A1**

(51) International Patent Classification<sup>7</sup>: **C07D 239/22**,  
401/04, 407/04, 409/12, A61K 31/505

(21) International Application Number: PCT/IB01/00707

(22) International Filing Date: 30 April 2001 (30.04.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/241,360 19 October 2000 (19.10.2000) US

(63) Related by continuation (CON) or continuation-in-part  
(CIP) to earlier application:  
US 60/241,360 (CON)  
Filed on 19 October 2000 (19.10.2000)

(71) Applicant (*for all designated States except US*): **NAEJA  
PHARMACEUTICAL INC.** [CA/CA]; 4290-91 A Street,  
Edmonton, Alberta R6E 5V2 (CA).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **SINGH, Rajeshwar**  
[CA/CA]; Naeja Pharmaceutical Inc., 4290-91 A Street,  
Edmonton, Alberta R6E 5V2 (CA). **REDDY, Andhe,**  
**V., N.** [CA/CA]; Naeja Pharmaceutical Inc., 4290-91 A  
Street, Edmonton, Alberta R6E 5V2 (CA). **ZHOU, Nian,**  
**E.** [CA/US]; 2204 Mercer Court, Napperville, IL 60565  
(US). **DING, Qizhu** [CA/CA]; Naeja Pharmaceutical Inc.,  
4290-91 A Street, Edmonton, Alberta T6E 5V2 (CA).

**THOMAS, George** [CA/CA]; Naeja Pharmaceutical Inc.,  
4290-91 A Street, Edmonton, Alberta R6E 5V2 (CA).  
**KALETA, Jadwiga** [CA/CA]; Naeja Pharmaceutical Inc.,  
4290-91 A Street, Edmonton, Alberta R6E 5V2 (CA).  
**MICETICH, Ronald, G.** [CA/CA]; Naeja Pharmaceutical  
Inc., 4290-91 A Street, Edmonton, Alberta R6E 5V2 (CA).

(74) Agents: **MURRAY, Robert, B.** et al.; Arent Fox Kintner  
Plotkin & Kahn, PLLC, 1050 Connecticut Avenue, N.W.,  
Suite 600, Washington, DC 20036 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,  
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,  
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,  
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,  
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 02/32879 A1

(54) Title: DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS

(57) Abstract: Ditiydropyrimidine derivatives are disclosed, which can be used to inhibit cysteine protease activity.

BEST AVAILABLE COPY

## DIHYDROPYRIMIDINE DERIVATIVES AS CYSTEINE PROTEASE INHIBITORS

[0001] This invention relates to novel derivatives of dihydropyrimidine, to pharmaceutical compositions containing such compounds, and to their use in medicine as inhibitors of lysosomal cysteine proteases, particularly the cathepsins and more particularly Cathepsins B, L, K and S.

**BACKGROUND OF THE INVENTION**

[0002] Cysteine proteinases contain a highly reactive cysteine sulfhydryl group and a histidine imidazole group within the active site of the enzyme and are known to play an important role in a number of disease states.

[0003] Cathepsin K can be secreted into the extracellular space and is involved in bone and cartilage remodelling. Cathepsin K is implicated in the pathogenesis of osteoporosis. Cathepsin K inhibitors can prevent osteoporosis in animal models (PNAS.1997. 94:14249-14254). Cathepsin L inhibitors have also been shown to inhibit osteoporosis (Bone, 1997. 20:465-471).

[0004] Cathepsin B and others have also been shown to be released extracellularly by various tumour cells and are thought to play a role in tumour invasion (Journal of cellular Physiology. 1992. 150:534-544).

[0005] The cathepsins have also been shown to play a role in rheumatoid arthritis (Arthritis and Rheumatism 1994. 37:236-247) and neuronal and cardiac ischaemia (European Journal of Neuroscience. 1998. 10:1723-1733).

[0006] Cathepsins S and L both play a role in the generation of free MHC class II molecules capable of binding antigenic peptides in the endosomes. These class II/peptide complexes move to the cell membrane and are involved in T lymphocyte activation. Inhibitors of Cathepsin S have been shown to inhibit allergic immune responses (Journal of Clinical Investigation. 1998. 101:2351-2363).

**[0007]** In addition to their role in the above diseases, cathepsins play a major role in the pathogenesis of infectious diseases. For example, cathepsins are used by the protozoal parasites *Plasmodium* (malaria) and *Trypanosoma* (Chagas Disease) to invade the human host and cathepsin inhibitors can inhibit experimental disease in both cases (Antimicrobial agents and chemotherapy. 1998. 42:2254-2258; Journal of Experimental Medicine. 1998. 188:725-734). Cysteine proteases are also virulence factors for some pathogenic bacteria (J. Biochem. 1998, 123:305-312, Biochimica et Biophysica Acta 2000, 1477:35-50).

**[0008]** Cysteine proteinase are inhibited by several types of peptide derived inhibitors such as peptidyl aldehydes (Eur. J. Biochem. 1982, 129, 33-41), chloromethyl ketones (Acta. Biol. Med. Ger. 1981, 40, 1503-1511), diazomethyl ketones (Biochemistry 1977, 16, 5857-5861), monofluoromethyl ketones (Biochemical Pharmacology 1992 44, 1201-1207), acyloxy methyl ketones (J. Med. Chem. 1994, 37, 1833-1840), O-acyl hydroxamates (Biochem. Biophys. Research Communications 1988, 155, 1201-1206), methyl sulphonium salts (J. Biol. Chem. 1988, 263, 2768-2772), epoxy succinyl derivatives (Agric. Biol. Chem. 1978, 42, 523-527), tetrahydrofuran-3-one (WO-50533, 1998), monobactams (USP-5986108, 1999; USP-5916887, 1999; USP-5959123, 1999) and oxapenams (USP-5905076, 1999; USP-5925633, 1999) without significantly inhibiting other classes of proteinases.

**[0009]** These inhibitors, in general, have a natural peptidyl affinity group and a reactive group towards the thiol of the cysteine residue of cysteine proteinase. Natural peptidyl affinity groups are an attractive starting point for drug discovery because they are essential to virtually every biochemical process. Unfortunately, the *in vivo* effectiveness of such compounds is not reflected as expected on the basis of *in vitro* inhibitory activity, which may be due to the specificity towards other proteinases and poor pharmacokinetics. However, there exists a continuing need to develop new cysteine proteinase inhibitors with high selectivity and lower toxicity.


**[0010]** In an effort to find more effective low molecular weight cysteine protease inhibitors for therapeutic uses, we have focused our attention on a

novel dihydropyrimidine class of compounds having substitutions at positions 2, 3 and 5 and inhibitors of cysteine proteinase particularly cathepsins, which is reported in the present invention. The novel route using appropriately substituted monobactams as starting material for synthesis of these compounds is also described.

### SUMMARY OF THE INVENTION

[0011] The present invention provides the certain derivatives of novel dihydropyrimidine, to pharmaceutical compositions containing such compounds, and to their use in medicine as inhibitors of lysosomal cysteine proteases, particularly the cathepsins and more particularly Cathepsins B, L, K and S.

[0012] In accordance with the present invention, there is provided novel dihydropyrimidine derivatives having the formula (I):




or the pharmaceutically acceptable salts, hydrate or solvate thereof.

[0013] The present invention makes available a new class of cysteine protease inhibitors, which are significantly different from those, reported earlier and with improved *in vivo* potency in laboratory rodents. These compounds are useful for the treatment of diseases mediated by cysteine protease activity, for example muscular dystrophy, osteoporosis, tumour metastasis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergic immune response, and protozoal or bacterial disease.

## DETAILED DESCRIPTION OF THE INVENTION

[0014] In accordance with the present invention, there is provided dihydropyrimidine derivatives of general formula (I):



or a pharmaceutical acceptable salt, hydrate or solvate thereof.

[0015] Wherein:

[0016] Y represents -C(O)-, -OC(O)-, -NHC(O)- or -S(O<sub>2</sub>)-;

[0017] R<sub>1</sub> represents hydrogen or an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group.

[0018] R<sub>2</sub> represents hydrogen or an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group.

[0019] R<sub>3</sub> represents H, R<sub>6</sub> and OR<sub>6</sub>, wherein R<sub>6</sub> is C<sub>1</sub>-C<sub>3</sub>alkyl, C<sub>2</sub>-C<sub>3</sub>alkenyl, C<sub>2</sub>-C<sub>3</sub>alkynyl, cycloalkyl, cycloalkenyl, aryl or a heterocyclic group.

[0020] R<sub>4</sub> and R<sub>5</sub> individually represent H or an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, cycloalkyl, cycloalkenyl, aryl, or heterocyclic group.

[0021] R<sub>4</sub> and R<sub>5</sub> together represents an oxo group or a C<sub>3</sub>-C<sub>6</sub> cyclic ring system, which may be further, substituted with hydroxyl, halogen, and amino and substituted amino groups.

**[0022]** The derivative of formula I having asymmetric carbon atoms represents both R and S diastereoisomers.

**[0023]** The derivative of formula I having double bonds represents both E and Z geometrical isomers.

**[0024]** Pharmaceutically acceptable salts of the compounds of this invention include the sodium, potassium, magnesium, calcium, hydrogen chloride, tartaric acid, succinic acid, fumaric acid, methanesulfonic acid and p-toluenesulfonic acid salts.

**[0025]** As used herein the term "(C<sub>1</sub>-C<sub>6</sub>) alkyl" or "lower alkyl" means a straight or branched chain alkyl moiety having from 1 to 6 carbon atoms, including for example, methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylprop-1-yl, 2-methylprop-2-yl, pentyl, 3-methylbutyl, and hexyl. Similar terms such as "(C<sub>1</sub>-C<sub>3</sub>) alkyl" are to be interpreted similarly.

**[0026]** As used herein the term "C<sub>2</sub>-C<sub>6</sub>alkenyl" means a straight or branched chain alkenyl moiety having from 2 to 6 carbon atoms having at least one double bond of either E or Z stereochemistry where applicable. The term includes, for example, vinyl, allyl, 1- and 2-butenyl and 2-methyl-2-propenyl. Similar terms such as "(C<sub>2</sub>-C<sub>3</sub>)alkenyl" are to be interpreted similarly.

**[0027]** As used herein the term "C<sub>2</sub>-C<sub>6</sub> alkynyl" means a straight chain or branched chain hydrocarbon groups having from two to six carbon atoms and having in addition one triple bond. This term would include for example, ethynyl, 1-propynyl, 1- and 2-butylnyl, 2-methyl-2-propynyl, 2-pentylnyl, 3-pentylnyl, 4-pentylnyl, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl. Similar terms such as "(C<sub>2</sub>-C<sub>3</sub>)alkynyl" are to be interpreted similarly.

**[0028]** As used herein the term "cycloalkyl" means a saturated alicyclic moiety having from 3-7 carbon atoms and includes, for example, cyclohexyl, cycloheptyl, cyclopentyl, cyclobutyl and cyclopropyl.

[0029] As used herein the term "halogen" means fluoro, chloro, bromo or iodo.

[0030] As used herein the term "aryl" refers to a mono-, bi- or tri-cyclic, substituted or unsubstituted, carbocyclic aromatic group, and to groups consisting of two covalently linked substituted or unsubstituted monocyclic carbocyclic aromatic groups. Illustrative of such groups is phenyl, biphenyl and naphthyl, tetrahydronaphthyl, dihydronaphthyl, and cyclohexyl phenyl.

[0031] As used herein the unqualified term "heterocyclic" means a 5-7 membered heterocyclic ring, which may be aromatic or non-aromatic, containing one or more heteroatoms selected from S, N and O, and optionally fused to a benzene or hetero-atom containing ring. The term therefore includes C<sub>1</sub>-C<sub>11</sub> heterocyclic groups containing 1-4 heteroatoms selected from N, S or O. Examples include 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3,4-tetrazolyl, thienyl, furyl, pyrrolyl, imidazolyl, pyridyl, pyrimidinyl, oxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, benzofuranyl, benzothiophenyl, benzimidazolyl, quinolinyl, isoquinolinyl, indolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, pyridylphenyl and pyrimidylphenyl groups.

[0032] As used herein, the unqualified term "substituted" as applied to a group means substituted with 1, 2, or 3 substituents selected from


(C<sub>1</sub>-C<sub>3</sub>)alkyl;  
phenyl;  
C<sub>3</sub>-C<sub>6</sub>cycloalkyl;  
heterocyclic;  
hydroxy or mercapto;  
(C<sub>1</sub>-C<sub>3</sub>)alkoxy or (C<sub>1</sub>-C<sub>3</sub>)alkylthio;  
phenoxy or phenylthio;  
benzyloxy, methylenedioxy, ethylenedioxy;  
halogen;  
trifluoromethyl;  
nitro;

cyano (-CN);  
carboxyl, esterified or protected carboxyl;  
amino, mono- or di-(C<sub>1</sub>-C<sub>3</sub>)alkylamino, or protected amino;  
(C<sub>1</sub>-C<sub>3</sub>)alkylcarbonyl- or (C<sub>1</sub>-C<sub>3</sub>)alkylcarbonylamino-;  
-CONH(C<sub>1</sub>-C<sub>3</sub>)alkyl or -CON[(C<sub>1</sub>-C<sub>3</sub>)alkyl] [(C<sub>1</sub>-C<sub>3</sub>)alkyl]; and  
-NH-C(=NR<sub>7</sub>)R<sub>8</sub> wherein R<sub>7</sub> is hydrogen, (C<sub>1</sub>-C<sub>3</sub>)alkyl, or an N-protecting group and R<sub>8</sub> is amino, mono- or di-(C<sub>1</sub>-C<sub>6</sub>)alkylamino, protected amino, or (C<sub>1</sub>-C<sub>3</sub>)alkyl.

**[0033]** As used herein the term "protecting group" when used in relation to an amino or carboxylic acid moiety in the compounds of this invention means a group which is used to render the amino or carboxylic acid moiety substantially non reactive, ie to neutralise its amino or carboxylic acid functionality. In this context, protected amino groups include amido and acylamino, protected hydroxy or mercapto groups include ethers and thioethers, protected carboxyl groups include esters, and imidazolyl, indolyl or guanidyl groups may be protected as t-butoxycarbonyl derivatives. These are only examples of the many protecting derivatives known in the art and the others known to a skilled person. Such protecting groups are of course well known, eg from the art of peptide synthesis, and are discussed in the widely used handbook by T.W. Greene and P.G.M. Wuts, Protective groups in Organic Synthesis, 2nd Edition, Wiley, New York 1991, and elsewhere in the chemical literature.

**[0034]** In accordance with the preferred embodiment of the second aspect of the present invention there is provided a derivatives of dihydropyrimidines of formula I





or a pharmaceutical acceptable salt, hydrate or solvate thereof

**[0035]** Wherein:

**[0036]** Y is selected from -C(O)-, -OC(O)-, or -S(O<sub>2</sub>)-;

**[0037]** R<sub>1</sub> is selected from isopropyl, cyclohexyl, phenyl, tert-butylphenyl, isopropylphenyl, 4-fluorophenyl, 4-methoxyphenyl, 3-pyridinyl, naphthyl, biphenyl, 3,4-methylenedioxy-phenyl, benzothienyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydronaphthyl; aminonaphthyl; or acetamidonaphthyl.

**[0038]** R<sub>2</sub> is selected from 2-fluoroethyl, cyclohexyl, phenyl, benzyloxyphenyl, t-butylphenyl, biphenyl, benzyl, phenethyl, guanidinobenzyl, amidinobenzyl, guanidinophenethyl, amidinophenethyl, benzyloxyphenyl, naphthyl, naphthylmethyl, naphthylethyl, morpholinophenyl, morpholinobenzyl, morpholinophenethyl, 4-(2-carboxy-2-amino ethyl)-phenyl, 4-(2-carboxy-2-amino ethyl)-phenethyl, 3-pyridyl-phenyl, 3-pyridyl-phenethyl, 3-tetrazolyl-phenyl; 3,4-methylenedioxy-phenyl; 3,4-ethylenedioxy-phenyl; tetrahydroquinolinyl; dihydroquinolinyl; benzothiophen-2-yl; 5-chloro-benzothiophen-2-yl; benzothiophen-2-yl-methyl, quinoline-2-yl; quinoline-2-yl-methyl, benzofuran-2-yl; 5-chloro-benzofuran-2-yl or benzofuran-2-yl-methyl.

**[0039]** R<sub>3</sub> is selected from hydrogen, methyl, ethyl, 2-fluoroethyl, methoxy, ethoxy, cyclopropyl,

[0040] R<sub>4</sub> and R<sub>5</sub> individually is selected from hydrogen, methyl, 2-fluoroethyl, t-butyl, t-butylmethyl, phenyl, fluorophenyl, cyclopentyl, cyclohexyl, pyridyl, carboxyphenyl, methylphenyl or furanyl.

[0041] R<sub>4</sub> and R<sub>5</sub> together are selected from oxo, cyclopentyl or cyclohexyl.

[0042] The derivative of formula I having asymmetric carbon atoms represents both R and S diastereoisomers.

[0043] The derivative of formula I having double bonds represents both E and Z geometrical isomers.

[0044] Pharmaceutically acceptable salts of the compounds of formula (I) are selected from sodium, potassium, magnesium or calcium salt of carboxylic group and hydrogen chloride, tartaric acid, succinic acid, fumaric acid, methanesulfonic acid, p-toluenesulfonic acid salt of amino group.

[0045] More specifically, the most preferred embodiments of the present invention include the following compounds:

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-phenyl-2, 3-dihydropyrimidine-6-(1H)one.

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-(2-fluorophenyl)-2, 3-dihydropyrimidine-6-(1H)one.

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-(3-fluorophenyl)-2, 3-dihydropyrimidine-6-(1H)one

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-(4-fluorophenyl)-2, 3-dihydropyrimidine-6-(1H)one

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-(2,4-difluorophenyl)-2, 3-dihydropyrimidine-6-(1H)one

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-benzyl-2, 3-dihydropyrimidine-6-(1H)one.

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2,2-spirocyclopentyl-2, 3-dihydropyrimidine-6-(1H)one

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2,2-spirocyclohexyl-2,  
3-dihydropyrimidine-6-(1H)one

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2,2-spirocyclohexyl-2,  
3-dihydropyrimidine-6-(1H)one

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-(pyridin-4-yl)-2, 3-  
dihydropyrimidine-6-(1H)one

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-(2-carboxyphenyl)-  
2, 3-dihydropyrimidine-6-(1H)one.

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-(4-carboxyphenyl)-  
2, 3-dihydropyrimidine-6-(1H)one.

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-methyl-2,3-  
dihydropyrimidine-6-(1H)one

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2,2-dimethyl-2, 3-  
dihydropyrimidine-6-(1H)one

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-tert-butylmethyl-2,  
3-dihydropyrimidine-6-(1H)one

5-[2-(Benzyloxy carbonyl)-amino-2-benzyl]-acetamidopyrimidin-2,6-dione.

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamidopyrimidin-2,6-dione.

5-[2-(Benzyloxy carbonyl)-amino-2-cyclohexylmethyl]-acetamidopyrimidin-2,6-  
dione.

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-(2,4-  
dimethylphenyl)-2, 3-dihydropyrimidine-6-(1H)one

5-[2-(3-Phenylpropionyl)-amino-2-isobutyl]-acetamido-2,2-spirocyclopentyl-2,  
3-dihydropyrimidine-6-(1H)one

5-[2-(3-Phenylpropionyl)-amino-2-isobutyl]-acetamido-2-(furan-2-yl)-2, 3-  
dihydropyrimidine-6-(1H)one


5-[2-(3-Phenylpropionyl)-amino-2-isobutyl]-acetamido-2,2-spirocycloheptyl-2,  
3-dihydropyrimidine-6-(1H)one.

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]-acetamido-2-(furan-2-yl)-2, 3-  
dihydropyrimidine-6-(1H)one

5-[2-(Benzothiophene-2-yl)-amino-2-isobutyl]-acetamido-2-(2-fluorophenyl)-2,  
3-dihydropyrimidine-6-(1H)one

5-[2-(4-Benzyloxybenzoyl)-amino-2-isobutyl]-acetamido-2-(furan-2-yl)-2, 3-  
dihydropyrimidine-6-(1H)one

[0046] In accordance with the preferred embodiment of the third aspect of the present invention there is provided a derivatives of dihydropyrimidines of formula I



or a pharmaceutical acceptable salt, hydrate or solvate thereof

[0047] Wherein:

[0048] Y is selected from -C(O)-;

[0049] R<sub>1</sub> is isopropyl, cyclohexyl and phenyl.

[0050] R<sub>2</sub> is t-butylphenyl, biphenyl, phenethyl, morpholinoethyl, benzothiophen-2-yl or benzofuran-2-yl.

[0051] R<sub>3</sub> is selected from hydrogen or methyl,

[0052] R<sub>4</sub> and R<sub>5</sub> individually is fluorophenyl, pyridyl, or furanyl.

[0053] R<sub>4</sub> and R<sub>5</sub> together is cyclopentyl or cyclohexyl.

[0054] The derivative of formula I having asymmetric carbon atoms represents both R and S diastereoisomers.

[0055] The derivative of formula I having double bonds represents both E and Z geometrical isomers.

**[0056]** Pharmaceutically acceptable salts of the compounds of formula (I) is sodium salt of carboxylic acid and hydrogen chloride salt of amino group.

**[0057]** As stated, the compounds of the invention are inhibitors of cysteine proteases, for example cathepsins B, L and S or K. The invention therefore also provides a pharmaceutical composition containing a compound of formula (I) as defined above, and a pharmaceutically acceptable carrier. Also provided is the use of such a compound in the preparation of a composition for inhibiting cysteine protease activity in the body of a mammal suffering a disease mediated by such activity, and a method of treatment of an animal suffering from a disease mediated by cysteine protease activity, which method comprises administering to the mammal a sufficient amount of a compound of formula (I) as defined above to inhibit such activity.

**[0058]** Diseases mediated by cysteine protease activity include muscular dystrophy, osteoporosis, tumour metastasis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergic immune response, and protozoal or bacterial disease.

**[0059]** Compositions with which the invention is concerned may be prepared for administration by any route consistent with the pharmacokinetic properties of the active ingredient(s).

**[0060]** Orally administrable compositions may be in the form of tablets, capsules, powders, granules, lozenges, liquid or gel preparations, such as oral, topical, or sterile parenteral solutions or suspensions. Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinyl-pyrrolidone; fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tableting lubricant, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants for example potato starch, or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions,

solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, glucose syrup, gelatin hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.

**[0061]** For topical application to the skin, the active ingredient(s) may be made up into a cream, lotion or ointment. Cream or ointment formulations, which may be used for the drug are conventional formulations well known in the art, for example as described in standard textbooks of pharmaceuticals such as the British Pharmacopoeia.

**[0062]** The active ingredient(s) may also be administered parenterally in a sterile medium. Depending on the vehicle and concentration used, the drug can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. Intravenous infusion is another route of administration for the compounds.


**[0063]** Safe and effective dosages for different classes of patient and for different disease states will be determined by clinical trial as is required in the art. It will be understood that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination and the severity of the particular disease undergoing therapy.

## DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0064] The present invention provides certain novel derivatives of dihydropyrimidine having excellent cysteine protease inhibitory activity particularly to cathepsins. The compounds of this invention are characterized by having a substitution at position 2, 3, and 5 of dihydropyrimidin-6-one.


[0065] Compounds of general formula I, reported in the present invention are prepared by the reaction of compound (II) with various aldehydes or ketones in appropriate solvents, which fall within the art of chemistry, as shown in the Scheme-1.

Scheme-1



Alternatively, the derivatives of general formula I was also prepared by the general synthetic route as represented in scheme II


Scheme-2



[0066] The compound III was treated with amines followed by a reaction with substituted aldehyde or ketones gave protected compound V. The benzyloxycarbonyl protected compound V was deprotected by hydrogenation in the presence of a metal catalyst, such as Pd, Pt, or Rh, under normal pressure to high pressure to give compound VI. Further, compound VI was reacted with substituted carboxylic acid VII in the presence of DCC, or with acid chlorides in the presence of base, or with anhydride in the presence of base or the activated ester, gave compound I.




[0067] The preparation of compound II was carried out by the synthetic procedure as described in Scheme-3.



Scheme-3

[0068] Alternatively compound II can also be prepared by following the synthetic scheme-4.

Scheme-4




[0069] The compound VII residue is defined as substitution at position-5 of 5-amino-dihydropyrimidin-6-one. The compound VII was coupled with aminoacetamide either in the presence of DCC, or with its acid chloride in the presence of base, or with its anhydride in the presence of base or with its activated ester.

[0070] In the above processes, the reactants are reacted together with solvent at elevated or low temperatures for sufficient time to allow the reaction to proceed to completion. The reaction conditions will depend upon the nature and reactivity of the reactants. Wherever a base is used in a reaction, it is selected from the group consisting of triethyl amine, pyridine, 4-dimethylaminopyridine, diisopropylamine, 1,5-diazabicyclo [4,3,0] non-5-ene, 1,8-diazabicyclo [5,4,0] undec-7-ene, sodium carbonate, potassium carbonate, cesium carbonate, sodium hydroxide, potassium hydroxide. Depending on the reactants, a solvent will generally be selected from the group consisting of benzene, toluene, acetonitrile, tetrahydrofuran, ethanol, methanol, chloroform, ethyl acetate, methylene chloride, dimethyl formamide, dimethyl sulfoxide, hexamethyl phosphoric triamide, water, pyridine, acetone, and the like. solvent mixtures may also be utilized. Reaction temperatures generally range from between -70 °C to 150 °C. The preferred molar ratio of reactants is 1:1 to 5. The reaction time range from 0.5 to 72 hours, depending on the reactants.

[0071] The following examples illustrate embodiments of the invention.

Example-1(NPI-3243)

5-[2-(Benzyloxy carbonyl)amino-2-isobutyl]acetamido-2-phenyl-2, 3-dihydropyrimidine-6-(1H)one.



[0072] A solution of 2-(2S-2-benzylloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide (1.78g) in methanol(100ml) was treated with benzaldehyde (5g) and refluxed for 10h. The solvent was removed *in vacuo*

and the residue was purified by silica gel column chromatography using a mixture of chloroform and methanol (5%) as to give the title compound.


Yield: 0.268g, 12%

m.p.: 76-78

$^1\text{H}$ NMR(DMSO- $d_6$ ):  $\delta$  0.85(m, 6H), 1.40-1.70(m, 3H), 4.00-4.20(m, 1H), 5.05(s, 2H), 5.62(s, 1H), 7.06(d, 1H,  $J=6.0\text{Hz}$ ), 7.20-7.50(m, 10H), 7.60-7.70(m, 2H), 7.78(s, 1H), 8.43(s, 1H).

Example-2(NPI-3392)

5-[2-(Benzyloxy carbonyl)amino-2-isobutyl]acetamido-2-(2-fluorophenyl)-2, 3-dihydropyrimidine-6-(1H)one.



[0073] The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and 2-fluorobenzaldehyde.


Yield: 8%

m.p.: 78-81 °C

$^1\text{H}$ NMR(DMSO- $d_6$ ):  $\delta$  0.83-0.89(m, 6H), 1.44-1.70(m, 3H), 4.06-4.18(m, 1H), 5.05(s, 2H), 5.91(s, 1H), 7.01-7.67(m, 12H), 7.79(s, 1H), 8.43(s, 1H).

Example-3(NPI-3474)

5-[2-(Benzyloxy carbonyl)amino-2-isobutyl]acetamido-2-(3-fluorophenyl)-2, 3-dihydropyrimidine-6-(1H)one



[0074] The title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and 3-fluorobenzaldehyde.


Yield: 17%

m.p.: 84-86 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.82-0.88(m, 6H), 1.41-1.73(m, 3H), 4.02-4.15(m, 1H), 5.04(s, 2H), 5.66(s, 1H), 7.19-7.70(m, 12H), 7.97(s, 1H), 8.39(s, 1H).

#### Example-4(NPI-3470)

5-[2-(Benzyloxy carbonyl)amino-2-isobutyl]acetamido-2-(4-fluorophenyl)-2, 3-dihydropyrimidine-6-(1H)one



[0075] The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and 4-fluorobenzaldehyde.


Yield: 23%

m.p.: 87-91 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.82-0.88(m, 6H), 1.33-1.74(m, 3H), 4.02-4.17(m, 1H), 5.05(s, 2H), 5.64(s, 1H), 7.07-7.72(m, 12H), 7.87(s, 1H), 8.39(s, 1H).

Example-5(NPI-3490)

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]acetamido-2-(2,4-difluorophenyl)-2,3-dihydropyrimidine-6-(1H)one



[0076] The title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and 2,4-difluorobenzaldehyde.


Yield: 9%

m.p.: 87-90 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.83-0.89(m, 6H), 1.45-1.74(m, 3H), 4.03-4.16(m, 1H), 5.05(s, 2H), 5.88(s, 1H), 7.00-7.35(m, 8H), 7.59-7.69(m, 2H), 7.81(s, 1H), 8.44(s, 1H).

Example-6(NPI-3469)

5-[2-(Benzyloxy carbonyl)amino-2-isobutyl]acetamido-2,2-spirocyclopentyl-2,3-dihydropyrimidine-6-(1H)one



[0077] The above title compound was synthesized by the procedure described for step-2 of example-1 and using the 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and cyclopentanone.


Yield: 3.4%

m.p.: 80-82 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.80-0.88(m, 6H), 1.41-1.92(m, 11H), 4.02-4.15(m, 2H), 5.05(s, 2H), 6.80(d, 1H, J=6.0Hz), 7.35(s, 5H), 7.56(d, 1H, J=6.0Hz), 7.58(s, 1H), 7.67(d, 1H, J=9.0Hz), 8.32(s, 1H).

#### Example-7(NPI-3481)

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]acetamido-2,2-spirocyclohexyl-2,3-dihydropyrimidine-6-(1H)one.



[0078] The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-

benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and cyclohexanone.


Yield: 4.5%

m.p.: 83-85 °C.

$^1\text{H}$ NMR(DMSO- $d_6$ ):  $\delta$  0.83-0.88(m, 6H), 1.15-1.94(m, 13H), 3.90-4.18(m, 2H), 5.02 and 5.05(2s, 2H), 6.68(d, 1H,  $J=6.0\text{Hz}$ ), 7.35(s, 6H), 7.54(d, 1H,  $J=6.0\text{Hz}$ ), 7.66(d, 1H,  $J=8.3\text{Hz}$ ), 8.31(s, 1H).

Example-8(NPI-3479)

5-[2-(Benzyloxy carbonyl)-amino -2-isobutyl]acetamido-2-tert-butyl-2, 3-dihydropyrimidine-6-(1H)one



**[0079]** The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and trimethyl acetaldehyde.


Yield: 4.5%

m.p.: 87-88 °C.

$^1\text{H}$ NMR(DMSO- $d_6$ ):  $\delta$  0.83-0.90(m, 15H), 1.40-1.72(m, 3H), 3.99-4.15(m, 1H), 4.20(s, 1H), 5.05(s, 2H), 6.54(d, 1H,  $J=5.0\text{Hz}$ ), 7.25-7.71(m, 8H), 8.35(d, 1H,  $J=2.5\text{Hz}$ ).

Example-9(NPI-3468)

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]acetamido-2-(pyridin-4-yl)-2, 3-dihydropyrimidine-6-(1H)one



**[0080]** The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and pyridine-4-carboxaldehyde.


Yield: 20.4%

m.p.: 97-99 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.84-0.88(m, 6H), 1.44-1.71(m, 3H), 3.90-4.00(m, 1H), 5.01(s, 2H, ), 5.47(d, 1H, J=8.1Hz), 6.37(br, s, 1H), 6.67-6.75(m, 2H), 7.36(s, 6H), 7.60-7.65(m, 1H), 8.59(s, 1H), 8.62(s, 1H), 8.71-8.90(m, 2H).

Example-10(NPI-3400)

5-[2-(Benzyloxy carbonyl)-amino -2-isobutyl]acetamido-2-tert-butylmethyl-2, 3-dihydropyrimidine-6-(1H)one





[0081] The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and 3,3-dimethylbutyraldehyde.


Yield: 13%

m.p.: 84-86 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.83-0.98(m, 15H), 1.45-1.64(m, 5H), 4.05-4.15(m, 1H), 4.54(s, 1H), 5.05(s, 2H), 6.45(d, 1H, J=4.3Hz), 7.26-7.35(m, 7H), 7.62-7.72(m, 2H), 8.35(m, 1H).

Example-11(NPI-3398)

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]acetamido-2-(2-carboxyphenyl)-2,3-dihydropyrimidine-6-(1H)one.



[0082] The title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and 3-carboxy benzaldehyde.


Yield: 3%

m.p.: 221-223 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.82-0.92(m, 6H), 1.43-1.76(m, 3H), 4.05-4.17(m, 1H), 5.05(s, 2H), 6.39(s, 1H), 6.80-6.88(m, 1H), 7.36-7.67(m, 10H), 7.96(d, 1H, J=7.6Hz), 8.41(s, 1H), 13.35(s, 1H).

Example-12(NPI-3397)

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]acetamido-2-(4-carboxyphenyl)-2,3-dihydropyrimidine-6-(1H)one.



[0083] The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and 4-carboxy benzaldehyde.


Yield: 13%

m.p.: 139-145 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.82-0.88(m, 6H), 1.35-1.80(m, 3H), 3.98-4.18(m, 1H), 5.04(s, 2H), 5.71(s, 1H), 7.20-7.98(m, 13H), 8.39(s, 1H), 13.04(s, 1H).

Example-13(NPI-3267)

5-[2-(Benzyloxy carbonyl)amino-2-benzyl]acetamido pyrimidin-2,6-dione



[0084] A mixture of N-benzyloxycarbonylamino-phenylalanine (0.429g, 1.433 mmol), DCC (0.296g, 1.433 mmol), 1-HBT (0.194g, 1.433 mmol) and 5-amino uracil (0.182g, 1.433 mmol) in dry DMF (10ml) was stirred at RT for 6 hrs and diluted with ethyl acetate. The ethyl acetate solution was washed with water, aq. sat.  $\text{NaHCO}_3$  solution followed by brine solution, dried over  $\text{MgSO}_4$ , filtered and evaporated. The crude product obtained was treated with isopropanol and the solid separated was filtered and dried to give the title compound.


Yield: 90.1%

m.p.: 229-230 °C

$^1\text{H}$ NMR( $\text{DMSO-d}_6$ ):  $\delta$  2.76-3.06(m, 2H), 4.50-4.60(m, 1H), 4.94(s, 2H), 7.23-7.40(m, 10H), 7.72(d, 1H,  $J=8.4\text{Hz}$ ), 8.10(s, 1H), 9.35(s, 1H), 11.15(br, s, 2H).

Example-14(NPI-3268)

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]acetamido pyrimidin-2,6-dione.



[0085] The above compound was prepared by the procedure described in example-13 and by using N-(benzyloxycarbonyl)amino leucine (0.511g, 1.93 mmol), DCC (0.397g, 1.93 mmol), 1-HBT (0.261g, 1.93 mmol) and 5-amino uracil (0.245, 1.93 mmol) in DMF (12ml).


Yield: 52.4%

m.p.: 205-206 °C

$^1\text{H}$ NMR(DMSO- $d_6$ ):  $\delta$  0.84-0.89(m, 6H), 1.35-1.70(m, 3H), 4.22-4.32(m, 1H), 5.04(s, 2H), 7.35(s, 5H), 7.70(d, 1H,  $J=8.1\text{Hz}$ ), 8.06(s, 1H), 9.06(s, 1H), 10.67(br s, 1H), 11.50(br s, 1H).

Example-15(NPI-3269)

5-[2-(Benzyloxy carbonyl)-amino-2-cyclohexylmethyl]-acetamido pyrimidin-2,6-dione



**[0086]** The above compound was prepared by the procedure described in example-13 and by using N-(benzyloxycarbonyl)amino cyclohexylalanine (0.505g, 1.654 mmol), DCC (0.341g, 1.654 mmol), 1-HBT (0.224g, 1.654 mmol) and 5-amino uracil (0.105, 1.654 mmol) in DMF (15ml).


Yield: 45%

m.p.: 204-205 °C

$^1\text{H}$ NMR(DMSO- $d_6$ ):  $\delta$  0.74-1.76(m, 13H), 4.25-4.35(m, 1H-), 5.05(s, 2H), 7.35(s, 5H), 7.69(d, 1H,  $J=8.0\text{Hz}$ ), 8.05(s, 1H), 9.04(s, 1H), 10.66(br s, 1H), 11.51(br s, 2H).

Example-16(NPI-3497)

5-[2-(Benzyloxy carbonyl)-amino-2-isobutyl]acetamido-2-(2,4-dimethylphenyl)-2,3-dihydropyrimidine-6-(1H)one



[0087] The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and 2,4-dimethyl benzaldehyde.


Yield: 5.1%

m.p.: 101-106 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.84-0.89(m, 6H), 1.45-1.70(m, 3H), 2.27 and 2.34(2s, 6H), 4.06-4.20(m, 1H), 5.06(s, 2H), 5.76(s, 1H), 6.79(d, 1H, J=5.0Hz), 7.03-7.42(m, 9H), 7.56(s, 1H), 7.71(d, 1H, J=6.2Hz), 8.42(s, 1H).

#### Example-17(NPI-4769)

5-[2-(3-Phenylpropionyl)-amino-2-isobutyl]acetamido-2,2-spirocyclopentyl-2,3-dihydropyrimidine-6-(1H)one



[0088] The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-[2S-2-(3-phenylpropionyl)-

amino-2-isopropylmethyl-acetamido]-3-amino-acrylamide and  
cyclopentanone.


Yield: 3.4 %

m.p.: 95 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.78-0.87(m, 6H), 1.39-1.94(m, 11H), 2.43-2.50(m, 2H), 2.80-2.90(m, 2H), 4.24-4.37(m, 1H), 6.82(d, 1H, J=6.5Hz), 7.13-7.33(m, 6H), 7.54(d, 1H, J=6.5Hz), 8.17(d, 1H, J=6.5Hz), 8.28(s, 1H).

Example-18(NPI-4772)

5-[2-(3-Phenylpropionyl)-amino-2-isobutyl]acetamido-2-(furan-2-yl)-2, 3-dihydropyrimidine-6-(1H)one



**[0089]** The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-(3-phenylpropionoyl)-amino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and furan-2-carboxaldehyde.


Yield: 4.4%

m.p.: 124 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.79-0.90(m, 6H), 1.40-1.50(m, 3H), 2.40-2.50(m, 2H), 2.77-2.88(m, 2H), 4.27-4.40(m, 1H), 5.67(s, 1H), 6.35-6.47(m, 2H), 7.10-7.30(m, 7H), 7.60(d, 1H, J=5.83Hz), 7.66(s, 1H), 7.91(s, 1H), 8.16(d, 1H, J=8.5Hz), 8.35(s, 1H).

Example-19(NPI-4774)

5-[2-(3-Phenylpropionyl)-amino-2-isobutyl]acetamido-2,2-spirocycloheptyl-2,3-dihydropyrimidine-6-(1H)one.



**[0090]** The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-(3-phenylpropionyl)-amino)-2-isopropylmethyl-acetamido)-3-amino-acrylamide and cycloheptanone.


Yield: 6.3%

m.p.: 125 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.80-0.90(m, 6H), 1.30-1.62(m, 10H), 1.74-2.00(m, 3H), 2.39-2.48(m, 2H), 2.78-2.89(m, 2H), 4.25-4.41(m, 1H), 6.74(d, 1H, J=6.3Hz), 7.10-7.51(m, 7H), 8.14(d, 1H, J=8.3Hz).

Example-20(NPI-3510)

5-[2-(Benzyloxy carbonyl)amino-2-isobutyl]acetamido- 2-(furan-2-yl)-2, 3-dihydropyrimidine-6-(1H)one



**[0091]** The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzyloxycarbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and furan-2-carboxaldehyde.


Yield: 4.8%

m.p.: 75-80<sup>0</sup> C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.85-0.90(m, 6H), 1.42-1.72(m, 3H), 4.03-4.17(m, 1H), 5.05(s, 2H), 5.68(s, 1H), 6.36(s, 1H), 6.43(s, 1H), 7.10(s, 1H), 7.35(s, 6H), 7.66(s, 2H), 7.92(s, 1H), 8.38(s, 1H).

#### Example-21(NPI-3493)

5-[2-(Benzothiophene-2-yl)amino-2-isobutyl]acetamido-2-(2-fluorophenyl)-2,3-dihydropyrimidine-6-(1H)one



**[0092]** The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-(2S-2-benzothien-2-yl-carbonylamino-2-isopropylmethyl-acetamido)-3-amino-acrylamide and 2-fluorobenzaldehyde.




Yield: 11.3%

m.p.: 119-123 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.90-0.94(m, 6H), 1.58-1.85(m, 3H), 4.56-4.68(m, 1H, ), 5.91(s, 1H), 7.08(d, 1H, J=5.0Hz), 7.20-7.65 (m, 8H), 7.75(s, 1H), 7.97-8.09(m, 2H), 8.27(s, 1H), 8.57(s, 1H), 8.93(d, 1H, J=8.4Hz).

#### Example-22(NPI-3522)

5-[2-(4-Benzyloxybenzoyl)amino-2-isobutyl]acetamido-2-(furan-2-yl)-2, 3-dihydropyrimidine-6-(1H)one



[0093] The above title compound was synthesized by the procedure described for step-2 of example-1 and using 2-[2S-2-(4-benzyloxybenzoylamino)-2-isopropylmethyl-acetamido]-3-amino-acrylamide and furan-2-carboxaldehyde.

Yield: 28%

m.p.: 103-105 °C

<sup>1</sup>HNMR(DMSO-d<sub>6</sub>): δ 0.90-0.97(m, 6H), 1.54-1.79(m, 3H), 4.50-4.62(m, 1H), 5.19(s, 2H), 5.66(s, 1H), 6.35-6.44(m, 2H), 7.08-7.12(m, 3H), 7.33-7.49(m, 6H), 7.67(s, 1H), 7.86-7.90(m, 3H), 8.40(s, 1H), 8.50(d, 1H, J=6.5Hz).

#### Biological Testing

[0094] Testing of inhibitors for inhibition of cathepsin B, L, K and S.

In vitro assay procedure for cathepsin B

[0095] The compounds of formula I were tested for inhibition of cathepsin B using the known method (A.J. Barret et al., Biochem. J. 1982, 201, 189-198). To a 170µl of enzyme-buffer mixture (enzyme: r rat cathepsin B, diluted to give approximate 10 F units/min, buffer: 56mM sodium acetate, 1.124mM EDTA, 10mM DTT, pH 5.1) a 10µl of inhibitor (dissolved in DMSO) was added. After 10min of incubation at room temperature, a 20µl of 5mM substrate (N-CBZ-Phe-Arg-AMC, dissolved in DMSO) was added to initiate reaction. Reading is followed up for 10 min at the fluoroscan reader (excitation at 380nm emission at 460nm).

[0096] A plot of percentage of inhibition vs inhibitor concentration is obtained, and  $IC_{50}$  is determined using a linear regression calculations (concentration of inhibitor which will give 50% inhibition).

In vitro assay procedure for cathepsin L

[0097] To a 170µl of enzyme-buffer mixture (enzyme: r rat cathepsin L, diluted to give approximate 15 F units/min, buffer: 58.8mM sodium citrate, 1.18mM EDTA, 235mM sodium chloride, 5mM DTT, pH 5.0) a 10µl of inhibitor (dissolved in DMSO) was added. After 10 min of incubation at room temperature, a 20µl of 1mM substrate (N-CBZ-Phe-Arg-AMC, dissolved in DMSO) was added to initiate reaction. Reading is followed up for 10 min at the fluoroscan reader (excitation at 380nm emission at 460nm).

[0098] A plot of percentage of inhibition vs inhibitor concentration is obtained, and  $IC_{50}$  is determined using a linear regression calculations (concentration of inhibitor which will give 50% inhibition).

In vitro assay procedure for cathepsin K

[0099] To a 170µl of enzyme-buffer mixture (enzyme: r cathepsin K, diluted to give approximate 30 F units/min, buffer: 100mM sodium acetate, 5mM EDTA, 20mM L-cysteine, 0.01% Brij, pH 5.5) a 10µl of inhibitor

(dissolved in DMSO) was added. After 10 min of incubation at room temperature, a 20 $\mu$ l of 2.7mM substrate (N-CBZ-Phe-Arg-AMC, dissolved in DMSO) was added to initiate reaction. Reading is followed up for 10 min at the fluoroscan II plate reader (excitation at 380nm emission at 460nm).

**[00100]** A plot of percentage of inhibition vs inhibitor concentration is obtained, and IC<sub>50</sub> is determined using a linear regression calculations (concentration of inhibitor which will give 50% inhibition).

In vitro assay procedure for cathepsin S

**[00101]** To a 170 $\mu$ l of enzyme-buffer mixture (enzyme: r cathepsin S, diluted to give approximate 30 F units/min, buffer: 100mM sodium phosphate, 1mM EDTA, 5mM DTT, 0.01% Brij, pH 6.5) a 10 $\mu$ l of inhibitor (dissolved in DMSO) was added. After 10 min of incubation at room temperature a 20 $\mu$ l of 1.2mM substrate (N-CBZ-Val-Val-Arg-AMC, dissolved in DMSO) was added to initiate reaction. Reading is followed up for 10 min at the fluoroscan II plate reader (excitation at 380nm emission at 460nm).

**[00102]** A plot of percentage of inhibition vs inhibitor concentration is obtained, and IC<sub>50</sub> is determined using a linear regression calculations (concentration of inhibitor which will give 50% inhibition).

Table-1: In vitro inhibitory activity of compounds with Cathepsins

Example No.	IC <sub>50</sub> (μM)			
	Cathepsin B	Cathepsin L	Cathepsin K	Cathepsin S
1	4.01	0.46	0.34	0.46
2	8.38	0.92	0.057	0.29
6	3.16	1.79	0.1	0.48
8	4.56	0.48	0.074	0.48
9	2.29	0.46	0.018	0.055
10	9.53	2.32	0.25	2.32
14	>50	>50	>50	>50
17	>50	>50	12.12	8.49
19	5.22	0.45	0.091	0.068
20	2.35	1.5	0.045	0.094
21	0.42	0.17	0.014	0.037


**[00103]** Selected compounds of present invention were tested in rodents. This class of compound has favorable pharmacokinetics at the oral dose of 5 mg/kg. The bioavailability is about 60-70%. The data is summarized in Table-2.

Table-2: Pharmacokinetic parameters of selected examples with mice after single oral dose of 5mg/kg

PK parameters	Example #6	Example # 21
C <sub>max</sub> (ug/ml)	3.83 ± 3.09	2.61 ± 1.84
AUC (ug.min/ml)	163.6 ± 21.25	51.20 ± 15.82
T <sub>1/2</sub> (hr)	1.63 ± 0.48	0.54 ± 0.39
Cl/F (ml/min)	0.617 ± 0.08	2.09 ± 0.72
V <sub>z</sub> /F (L/kg)	4.49 ± 1.9	4.49 ± 3.03

## Claims:

1. In accordance with the present invention, there is provided novel dihydropyrimidine derivatives of general formula (I):



Wherein:

Y represents -C(O)-, -OC(O)-, -NHC(O)- or -S(O<sub>2</sub>)-;

R<sub>1</sub> represents hydrogen or an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group.

R<sub>2</sub> represents hydrogen or an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, cycloalkyl, cycloalkenyl, aryl or heterocyclic group.

R<sub>3</sub> represents H, R<sub>6</sub> and OR<sub>6</sub>, wherein R<sub>6</sub> is C<sub>1</sub>-C<sub>3</sub>alkyl, C<sub>2</sub>-C<sub>3</sub>alkenyl, C<sub>2</sub>-C<sub>3</sub>alkynyl, cycloalkyl, cycloalkenyl, aryl or a heterocyclic group.

R<sub>4</sub> and R<sub>5</sub> individually represent H or an optionally substituted C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, cycloalkyl, cycloalkenyl, aryl, or heterocyclic group.

R<sub>4</sub> and R<sub>5</sub> together represents an oxo group or a C<sub>3</sub>-C<sub>6</sub> cyclic ring system, which may be further, substituted with hydroxyl, halogen, and amino and substituted amino groups.

or a pharmaceutically acceptable salt, hydrate or solvate thereof

2. A compound according to claim 1 wherein the unqualified term "substituted" as applied to a group means substituted with 1, 2, or 3 substituents selected from

(C<sub>1</sub>-C<sub>3</sub>)alkyl;

phenyl;

C<sub>3</sub>-C<sub>6</sub>cycloalkyl;

heterocyclic;

hydroxy or mercapto;

(C<sub>1</sub>-C<sub>3</sub>)alkoxy or (C<sub>1</sub>-C<sub>3</sub>)alkylthio;

phenoxy or phenylthio;

benzyloxy, methylenedioxy, ethylenedioxy;

halogen;

trifluoromethyl;

nitro;

cyano (-CN);

carboxyl, esterified or protected carboxyl;

amino, mono- or di-(C<sub>1</sub>-C<sub>3</sub>)alkylamino, or protected amino;

(C<sub>1</sub>-C<sub>3</sub>)alkylcarbonyl- or (C<sub>1</sub>-C<sub>3</sub>)alkylcarbonylamino-;

-CONH(C<sub>1</sub>-C<sub>3</sub>)alkyl or -CON[(C<sub>1</sub>-C<sub>3</sub>)alkyl] [(C<sub>1</sub>-C<sub>3</sub>)alkyl]; and


-NH-C(=NR<sub>7</sub>)R<sub>8</sub> wherein R<sub>7</sub> is hydrogen, (C<sub>1</sub>-C<sub>3</sub>)alkyl, or an N-protecting group and R<sub>8</sub> is amino, mono- or di-(C<sub>1</sub>-C<sub>6</sub>)alkylamino, protected amino, or (C<sub>1</sub>-C<sub>3</sub>)alkyl.

3. A compound according to claim 1 wherein the term "(C<sub>1</sub>-C<sub>6</sub>) alkyl" or "lower alkyl" means a straight or branched chain alkyl moiety having from 1 to 6 carbon atoms, including for example, methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylprop-1-yl, 2-methylprop-2-yl, pentyl, 3-methylbutyl, and hexyl. Similar terms such as "(C<sub>1</sub>-C<sub>3</sub>) alkyl" are to be interpreted similarly.

4. A compound according to claim 1 wherein the term "C<sub>2</sub>-C<sub>6</sub>alkenyl" means a straight or branched chain alkenyl moiety having from 2 to 6 carbon atoms having at least one double bond, for example, vinyl, allyl, 1- and 2-butenyl and 2-methyl-2-propenyl. Similar terms such as "(C<sub>2</sub>-C<sub>3</sub>)alkenyl" are to be interpreted similarly.
5. A compound according to claim 1 wherein the term "C<sub>2</sub>-C<sub>6</sub> alkynyl" means a straight chain or branched chain hydrocarbon groups having from two to six carbon atoms and having in addition one triple bond, for example, ethynyl, 1-propynyl, 1- and 2-butyne, 2-methyl-2-propynyl, 2-pentyne, 3-pentyne, 4-pentyne, 2-hexynyl, 3-hexynyl, 4-hexynyl and 5-hexynyl. Similar terms such as "(C<sub>2</sub>-C<sub>3</sub>)alkynyl" are to be interpreted similarly.
6. A compound according to claim 1 wherein the term "cycloalkyl" means a saturated alicyclic moiety having from 3-7 carbon atoms and includes, for example, cyclohexyl, cycloheptyl, cyclopentyl, cyclobutyl and cyclopropyl.
7. A compound according to claim 1 wherein the term "aryl" refers to a mono-, bi- or tri-cyclic, substituted or unsubstituted, carbocyclic aromatic group, and to groups consisting of two covalently linked substituted or unsubstituted monocyclic carbocyclic aromatic groups, for example phenyl, biphenyl and naphthyl, tetrahydronaphthyl, dihydronaphthyl, and cyclohexyl phenyl.
8. A compound according to claim 1 wherein the unqualified term "heterocyclic" means a 5-7 membered heterocyclic ring, which may be aromatic or non-aromatic, containing one or more heteroatoms selected from S, N and O, and optionally fused to a benzene or heteroatom containing ring, for examples 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,3,4-tetrazolyl, thienyl, furyl, pyrrolyl, imidazolyl, pyridyl, pyrimidinyl,

oxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyrrolidinyl, morpholinyl, thiomorpholinyl, piperazinyl, piperidinyl, benzofuranyl, benzothiophenyl, benzimidazolyl, quinolinyl, isoquinolinyl, indolyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, pyridylphenyl and pyrimidylphenyl groups.

9. In accordance with the preferred embodiment of the second aspect of the present invention there is provided a derivatives of



dihydropyrimidines of formula I

Wherein:

Y is selected from -C(O)-, -OC(O)-, or -S(O<sub>2</sub>)-;

R<sub>1</sub> is selected from isopropyl, cyclohexyl, phenyl, tert-butylphenyl, isopropylphenyl, 4-fluorophenyl, 4-methoxyphenyl, 3-pyridinyl, naphthyl, biphenyl, 3,4-methylenedioxy-phenyl, benzothienyl, quinolinyl, isoquinolinyl, tetrahydroquinolinyl, tetrahydronaphthyl; aminonaphthyl; or acetamidonaphthyl.

R<sub>2</sub> is selected from 2-fluoroethyl, cyclohexyl, phenyl, benzyloxyphenyl, t-butylphenyl, biphenyl, benzyl, phenethyl, guanidinobenzyl, amidinobenzyl, guanidinophenethyl, amidinophenethyl, benzyloxyphenyl, naphthyl, naphthylmethyl, naphthylethyl, morpholinophenyl, morpholinobenzyl, morpholinophenethyl, 4-(2-carboxy-2-amino ethyl)-phenyl, 4-(2-carboxy-2-amino ethyl)-phenethyl, 3-pyridyl-phenyl, 3-pyridyl-phenethyl, 3-tetrazolyl-phenyl; 3,4-methylenedioxy-phenyl; 3,4-ethylenedioxy-phenyl; tetrahydroquinolinyl; dihydroquinolinyl; benzothiophen-2-yl; 5-chloro-benzothiophen-2-yl;



benzothiophen-2-yl-methyl, quinoline-2-yl; quinoline-2-yl-methyl, benzofuran-2-yl; 5-chloro-benzofuran-2-yl or benzofuran-2-yl-methyl.


R<sub>3</sub> is selected from hydrogen, methyl, ethyl, 2-fluoroethyl, methoxy, ethoxy, cyclopropyl,

R<sub>4</sub> and R<sub>5</sub> individually is selected from hydrogen, methyl, 2-fluoroethyl, t-butyl, t-butylmethyl, phenyl, fluorophenyl, cyclopentyl, cyclohexyl, pyridyl, carboxyphenyl, methylphenyl or furanyl.

R<sub>4</sub> and R<sub>5</sub> together are selected from oxo, cyclopentyl or cyclohexyl.

or a pharmaceutically acceptable salt, hydrate or solvate thereof

10. In accordance with the preferred embodiment of the third aspect of the present invention there is provided a derivatives of dihydropyrimidines of formula I



Wherein:

Y is selected from -C(O)-;

R<sub>1</sub> is isopropyl, cyclohexyl and phenyl.

R<sub>2</sub> is t-butylphenyl, biphenyl, phenethyl, morpholinoethyl, benzothiophen-2-yl or benzofuran-2-yl.

R<sub>3</sub> is selected from hydrogen or methyl,

R<sub>4</sub> and R<sub>5</sub> individually is fluorophenyl, pyridyl, or furanyl.

R<sub>4</sub> and R<sub>5</sub> together is cyclopentyl or cyclohexyl.

or a pharmaceutical acceptable salt, hydrate or solvate thereof

11. As used herein the term "halogen" means fluoro, chloro, bromo or iodo
12. A compound according to claim 1 wherein the derivative of formula I having asymmetric carbon atoms represents both R and S diastereoisomers.
13. A compound according to claim 1 wherein the derivative of formula I having double bonds represents both E and Z geometrical isomers.
14. A compound according to claim 1 wherein pharmaceutically acceptable salts of the compounds of formula (I) are selected from sodium, potassium, magnesium or calcium salt of carboxylic group and hydrogen chloride, tartaric acid, succinic acid, fumaric acid, methanesulfonic acid, p-toluenesulfonic acid salt of amino group.
15. A pharmaceutical composition containing a compound as claimed in any of the preceding claims and a pharmaceutically acceptable carrier.
16. The use of a compound as claimed in any of claims 1 to 14 in the preparation of a composition for inhibiting cysteine protease activity particularly cathepsins in the body of a mammal suffering a disease mediated by such activity.
17. A method of treatment of an animal suffering from a disease mediated by cysteine protease activity, which method comprises administering to

the mammal a sufficient amount of a compound as claimed in any of claims 1 to 14 to inhibit such activity.

18. The use as claimed in claim 16 or a method as claimed in claim 17 wherein the disease is muscular dystrophy, osteoporosis, tumour metastasis, rheumatoid arthritis, neuronal or cardiac ischaemia, allergic immune response, and protozoal or bacterial diseases.

# INTERNATIONAL SEARCH REPORT

In national Application No  
PCT/IB 01/00707

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D239/22 C07D401/04 C07D407/04 C07D409/12 A61K31/505

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, PAJ, WPI Data, BIOSIS, CHEM ABS Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 98 50533 A (FENWICK ASHLEY EDWARD ;GRIBBLE ANDREW D (GB); SMITHKLINE BEECHAM P) 12 November 1998 (1998-11-12) abstract; claims ---	1-18
A	WO 98 12210 A (SYNPHAR LAB INC ;CANADA NAT RES COUNCIL (CA)) 26 March 1998 (1998-03-26) abstract; claims ---	1-18
A	WO 00 59881 A (MICETICH RONALD G ;KALETA JADWIGA (CA); SINGH RAJESHWAR (CA); NAEJ) 12 October 2000 (2000-10-12) abstract; claims ---	1-18
	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex

\* Special categories of cited documents .

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*Z\* document member of the same patent family

Date of the actual completion of the international search

12 November 2001

Date of mailing of the international search report

19/11/2001

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Palenlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Frelon, D

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB 01/00707

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A, P	WO 01 09169 A (THOMAS GEORGE ;ZHOU NIAN (CA); DING QIZHU (CA); KALETA JADWIGA (CA) 8 February 2001 (2001-02-08) abstract; claims ---	1-18
A, P	PATENT ABSTRACTS OF JAPAN vol. 2000, no. 22, 9 March 2001 (2001-03-09) -& JP 2001 139534 A (NAGAO YOSHIMITSU;KATSUNUMA NOBUHIKO; SENJU PHARMACEUT CO LTD), 22 May 2001 (2001-05-22) abstract -----	1-18

## INTERNATIONAL SEARCH REPORT

In International Application No  
PCT/IB 01/00707

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9850533	A	12-11-1998	AU 7562598 A	27-11-1998
			BR 9809306 A	04-07-2000
			CN 1255161 T	31-05-2000
			EP 1003846 A1	31-05-2000
			HU 0002247 A2	28-05-2001
			NO 995434 A	05-11-1999
			PL 336856 A1	17-07-2000
			TR 9902766 T2	21-02-2000
			WO 9850533 A1	12-11-1998
			ZA 9803762 A	06-11-1998
WO 9812210	A	26-03-1998	AU 718918 B2	20-04-2000
			AU 4133597 A	14-04-1998
			EP 0929571 A1	21-07-1999
			WO 9812210 A1	26-03-1998
			JP 2001501193 T	30-01-2001
			US 6034077 A	07-03-2000
			US 5916887 A	29-06-1999
WO 0059881	A	12-10-2000	AU 3570000 A	23-10-2000
			WO 0059881 A1	12-10-2000
WO 0109169	A	08-02-2001	AU 6007200 A	19-02-2001
			WO 0109169 A2	08-02-2001
JP 2001139534	A	22-05-2001	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**